Celldex Therapeutics Announces Upcoming Presentation of Barzolvolimab Phase 1b Results in Chronic Spontaneous Urticaria at American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting 2023

Rhea-AI Summary

Celldex Therapeutics (NASDAQ:CLDX) announced the presentation of data from its Phase 1b multi-dose study of barzolvolimab for chronic spontaneous urticaria at the AAAAI Annual Meeting 2023, occurring from February 24-27 in San Antonio, Texas. The presentation is scheduled for February 26th, showcasing data through 24 weeks for cohorts receiving varying dosages (0.5, 1.5, 3.0, and 4.5 mg/kg). New data will be highlighted, with the company hosting a live webcast on the same day at 4:00 pm CT. This study represents a critical step in the development of treatments targeting inflammatory diseases.

Positive

• Presentation of new data at AAAAI Annual Meeting enhances visibility.
• Phase 1b study indicates ongoing development of barzolvolimab for chronic spontaneous urticaria.

Negative

• None.

Company to host webcast on Sunday, February 26 at 4:00 pm CT/5:00 pm ET

HAMPTON, N.J., Feb. 03, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that data from the Company’s Phase 1b multi-dose study of barzolvolimab in chronic spontaneous urticaria will be presented at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting 2023 being held February 24-27 in San Antonio, Texas. Abstracts will be available on the meeting website today, February 3, 2023.

Presentation Details:

Session Date & Time: Sunday, February 26th at 9:45 am - 10:45 am CT (10:45 am ET – 11:45 am ET)
Poster No. 308: Safety and Clinical Activity of Multiple Doses of Barzolvolimab, an anti-KIT Antibody, in Patients with Chronic Spontaneous Urticaria
Presenting Author: Marcus Maurer, M.D., Professor of Dermatology and Allergy at Charité - Universitätsmedizin in Berlin

Data included in the abstract are through May 2022. New data will be presented at the AAAAI meeting and will include the following:

• Data through 24 weeks for Cohorts 1-3 (0.5, 1.5 and 3.0 mg/kg doses)
• Data through 20 weeks for Cohort 4 (4.5 mg/kg dose); 6 of 9 patients available at this timepoint as of the data cut-off date

Webcast and Conference Call
The Company will host a webcast presentation of the data on Sunday, February 26^th at 4:00 pm CT (5:00 pm ET). The event will be webcast live and can be accessed by going to the "Events & Presentations” page under the "Investors & Media" section of the Celldex Therapeutics website at www.celldex.com.

About Celldex Therapeutics, Inc.
Celldex is a clinical stage biotechnology company dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate. Our pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with inflammatory diseases and many forms of cancer. Visit www.celldex.com.

Company Contact
Sarah Cavanaugh
Senior Vice President, Corporate Affairs & Administration
(508) 864-8337
scavanaugh@celldex.com

Patrick Till
Meru Advisors
(484) 788-8560
ptill@meruadvisors.com

FAQ

What is the purpose of the Phase 1b study of barzolvolimab by Celldex (CLDX)?

The Phase 1b study aims to evaluate the safety and clinical activity of barzolvolimab in patients with chronic spontaneous urticaria.

When will the data from the barzolvolimab study be presented?

The data will be presented on February 26, 2023, during the AAAAI Annual Meeting.

What new data will be revealed regarding barzolvolimab at the AAAAI meeting?

The presentation will include data through 24 weeks for various dosage cohorts and additional insights on the safety and clinical activity of the treatment.

How can investors access the webcast presentation by Celldex (CLDX)?

Investors can access the webcast live on February 26, 2023, via the 'Events & Presentations' page on the Celldex Therapeutics website.